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Cardiac surgery has undergone dramatic advancements with a brief historical background followed by a review of 
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cardiotonic and vasoactive drugs and advancements in 
anesthetic management, postoperative monitoring and 
nursing care greatly facilitate perioperative patient man- 
agement. 
This summary of state of the art cardiac surgery begins 
Coronary Artery Disease 
Coronary bypass surgery. Surgical management of ath- 
erosclerotic coronary artery disease began in the mid 1950s 
with the introduction of coronary endarterectomy by Bailey 
(1 I and Longmire (2) and their co-workers. These procedures 
were performed on the beating heart without cardiopulmo- 
nary bypass. In 1961, Goetz et al. (3) performed a nonsuture 
anastomosis over a tantalum ring between the right internal 
mammary artery and the right coronary artery. The first 
reversed saphenous vein bypass graft was performed by 
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Garrett in 1964 (4). In 1968, Favaloro (5) reported his 
landmark series of 15 patients who underwent reversed 
saphenous vein bypass of segmentally occluded right domi- 
nant coronary arteries. These bypass procedures were also 
performed on a beating heart with intermittent anoxic arrest. 
Anoxic arrest, with or without hypothermia, resulted in a 
9% to 20% intraoperative or early postoperative myocardial 
This article is part qf a series of articles celebrating 
the 40th anniversary of the American College of 
Cardiology. The serie.y attempts to set the stage for the 
future by describing current state of the art manage- 
ment of .selected major cardiovascular problems and 
the basic knowledge that will provide directions for 
advances in diagnosis and therapy. 
0735-109738963.50 
536 RICHENBACHER ET AL. JACC Vol. 14, No. 3 
CARDIAC SURGERY September 198953544 
infarction rate (6). Early results of coronary artery bypass 
improved with the introduction of hypothermia and induced 
ventricular fibrillation without anoxic arrest (7). A desire to 
reduce the metabolic demands of ischemic myocardium led 
Melrose et al. (8) to develop cold, hypertonic potassium 
citrate blood cardioplegia in 1955. The recognition that this 
procedure was associated with irreversible postoperative left 
ventricular injury led to its subsequent abandonment (9). 
Interest in cardioplegic arrest was rekindled when Gay and 
Ebert (10) documented a fourfold reduction in myocardial 
oxygen consumption in hearts preserved with high potas- 
sium cardioplegia as compared with the beating and non- 
working, paced or fibrillating heart. 
Twenty-four thousand coronary bypass operations were 
performed in the United States in 1971; by 1980 that number 
exceeded 125,000 (11). Current indications for aortocoro- 
nary bypass grafting include class III angina that is unre- 
sponsive to medical therapy, unstable angina, left main 
coronary artery stenosis and symptomatic status triple ves- 
sel disease (11). Percutaneous transluminal coronary angio- 
plasty, introduced into the clinical arena by Gruentzig in 
1979 (12), is ideally reserved for the coronary bypass surgery 
candidate who has one or two noncalcified, high grade 
stenoses of the proximal left anterior descending, right or left 
circumflex coronary artery. 
Surgery afIer myocardi infarction. Traditional teaching 
states that myocardial revascularization should either be 
undertaken within 4 to 6 h of the onset of an acute myocar- 
dial infarction or be delayed in an effort to avoid reperfusion 
injury. Katz et al. (13) evaluated 145 patients who underwent 
coronary artery bypass surgery within 4 weeks of an acute 
myocardial infarction. Postoperative heart failure was a 
strong predictor of mortality and was related to the presence 
of preoperative heart failure, ischemia and a low ejection 
fraction. Their study indicated that, whereas ischemia and 
congestive failure did influence mortality, the time after 
infarction did not, thus suggesting that myocardial revascu- 
larization should proceed without delay in the presence of 
ongoing ischemia or life-threatening coronary anatomy. 
Effect of coronary angioplasty on surgical revasculariza- 
tion. Coronary angioplasty has had a significant effect on 
coronary bypass surgery in that angioplasty removes low 
risk patients from the surgical candidate pool. The number of 
operative risk factors, including advanced age, female gen- 
der, severity of angina, triple vessel disease and left ventric- 
ular dysfunction, has increased among patients currently 
undergoing coronary artery bypass surgery (14-16). Naun- 
heim et al. (15) reported an increase from 3% to 7% in 
operative mortality for coronary bypass procedures during 
the past 10 years due, in part, to the inclusion of more high 
risk patients in the surgically treated population. These 
authors point out, however, that the clinical profile of 
current angioplasty patients closely resembles that of the 
coronary artery bypass patients of 1975. Other studies (16) 
have demonstrated that, despite an increase in risk factors, 
operative mortality can be maintained at a low rate. Two 
reports (17,18) have shown that coronary artery bypass 
surgery can be offered to patients in their 8th or 9th decade 
of life with acceptable results. 
Failed coronary angioplasty procedures also contribute 
to the group of patients requiring emergency myocardia! 
revascularization. Patients who require an emergency oper- 
ation after unsuccessful angioplasty have a higher mortality 
rate and greater incidence of postoperative hemorrhage, 
cardiac tamponade, myocardial infarction and length of 
hospitalization than do patients who undergo elective coro- 
nary artery bypass surgery (19). Ferguson et al. (20) concur 
but have shown that mortality and nonhemorrhagic compli- 
cation rates among patients who undergo coronary artery 
bypass surgery after failed elective coronary angioplasty are 
comparable with those in patients who undergo coronary 
artery bypass after failed emergency angioplasty. 
Surgery in acute myocardial infarction. Patients with an 
acute myocardial infarction who undergo thrombolysis may 
subsequently require emergency bypass surgery or coronary 
angioplasty. Bypass grafting yields excellent long-term re- 
sults, especially in patients with an ischemic interval of 
<3h (21). Results with either method of primary revascular- 
ization are comparable, although mortality remains highest 
in patients who have had unsuccessful angioplasty and 
require an emergency operation (22). 
Results of surgery versus angioplasty. The efficacy of 
coronary artery bypass surgery and coronary angioplasty in 
selected patients with one and two vessel coronary artery 
disease is well established. Gruentzig et al. (23) reported on 
169 patients who were followed up for 5 to 8 years after 
coronary angioplasty. They noted that, in their initial expe- 
rience, angioplasty was successful in 79% of cases, while 
30% of patients developed recurrent stenoses within 6 
months. As more recent randomized, prospective follow-up 
studies are reported, Daily (24) notes that the results of 
coronary angioplasty should be comparable with the results 
of bypass surgery in the pre-angioplasty era (similar risk 
groups). His benchmark for coronary angioplasty includes a 
complete revascularization rate of 99.8%, a hospital mortal- 
ity rate of 0.2%, a perioperative myocardial infarction rate of 
2.2%, a 5 year survival rate of 89.8% and freedom from 
reintervention at 5 years of 97.7%. 
Internal mammary artery grafts. The internal mammary 
artery remains the coronary bypass graft of choice (25). Zeff 
et al. (26) followed up 80 patients with a left anterior 
descending coronary artery bypass graft (41 patients with a 
saphenous vein graft, 39 with a left internal mammary artery 
graft) for 10 years and reported a lower mortality and higher 
patency rate in the patients with an internal mammary artery 
graft. In an effort to maximize the number of distal internal 
mammary artery anastomoses, sequential (271, bilateral and 
free internal mammary artery grafts have been employed. 
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Bilateral internal mammary artery grafts provide excellent 
conduits with which to revascularize the left anterior de- 
scending, left anterior descending diagonal and marginal 
coronary arteries (2X). Ten year follow-up studies show 
significantly greater freedom from reoperation and infarction 
and significantly lower rates of recurrent angina in the 
patients with internal mammary artery grafts than in those 
with saphenous vein grafts (28). Furthermore, the use of 
bilateral internal mammary artery grafts does not increase 
patient mortality or morbidity. with the exception of a slight 
increase in mean transfusion requirement, over that of 
patients with saphenous vein grafts (29). The posterior and 
diaphragmatic surfaces of the heart, inaccessible to in situ 
internal mammary artery grafts, can be bypassed with free 
internal mammary artery grafts. Concern that division of the 
internal mammary artery pedicle would result in reduced 
long-term graft patency and patient survival appears to be 
unfounded (30,31). Passage of the right internal mammary 
artery through the transverse sinus (27) and use of the distal 
internal mammary artery as a retrograde mammary bypass 
graft (32) are not recommended. Internal mammary artery 
grafts can be used in patients with smaller body habitus (33) 
and vasoactive drugs do not appear to reduce internal 
mammary artery flow (34). 
Transfusion requirements and precautions. Transfusion- 
related infectious disease has been featured prominently in 
the lay press because of increased public concern over 
acquired immunodeficiency syndrome. Approximately 2% 
of acquired immunodeficiency syndrome cases in the United 
States have resulted from transfusion of blood or blood 
products (35). As a large number of transfusion-related 
acquired immunodeficiency syndrome infections occur after 
cardiac operations (36), attention has recently been directed 
to perioperative blood conservation. Both intraoperative 
autotransfusion of washed red blood cells (37) and postop- 
erative reinfusion of shed mediastinal blood (38) decrease 
the need for homologous transfusion. Transfusion require- 
ments can also be reduced by the avoidance of aspirin 
preoperatively (39) and the perioperative administration of 
dipyridamole (40). In the event nonsurgical postoperative 
bleeding occurs, the transfusion of 1 U of fresh whole blood 
has a hemostatic effect equal, if not superior, to that of IO U 
of platelets (41). Moreover, the number of donors is mini- 
mized, thereby reducing the risk of exposure to blood-borne 
viruses. 
Acquired Valvular Disease 
Mitral Valve Disease 
Mitral stenosis. The first valve operations attempted to 
correct rheumatic mitral stenosis without the use of cardio- 
pulmonary bypass. Closed mitral commissurotomy was ac- 
complished by transatrial digital dilation (42), transapical 
partial valvulectomy (43) and transventricular mechanical 
dilation (44). The introduction of cardiopulmonary bypass 
made possible mitral valve replacement. The first mitral 
valve prosthesis, constructed of woven Teflon fabric, was 
implanted by Kay et al. (4.5) in 1960. The Starr-Edwards 
ball-valve (Baxter Healthcare Corporation), the first true 
mechanical valve prosthesis, was implanted in the mitral 
position in I%1 (46). 
Despite 30 years of experimental and clinical experience, 
the ideal prosthetic valve has yet to be manufactured. The 
70” convexo-concave Bjork-Shiley valve (Shiley Inc.) has an 
increased incidence of outlet strut fractures (47) and is no 
longer commercially available. The 7 year actuarial inci- 
dence of mechanical failure in the 29 to 3 1 mm, 70” convexo- 
concave Bjork-Shiley valve is 12..5%, regardless of whether 
the valve is placed in the aortic or mitral position (48). Bjiirk 
and coworkers (48) have recently recommended that se- 
lected patients with an early production valve of this type be 
considered for re-replacement. A newer, more durable, 
monostrut Bjbrk-Shiley valve has been implanted in 486 
patients (537 prostheses) with no structural failures noted at 
an average follow-up interval of 33 months (49). 
The Edwards-Duromedics bileaflet valve (Baxter Health- 
care Corporation) has developed mechanical failure due to 
fatigue-related leaflet fractures and is also no longer com- 
mercially available (50). At present, patients with this valve 
require careful long-term follow-up, but prophylactic re- 
replacement has not been recommended. 
The Starr-Edwards prosthesis remains the standard 
against which other mechanical and tissue valves must be 
compared. Starr et al. (51) reported on 707 patients with a 
Starr-Edwards valve with follow-up extending beyond 20 
years (mean 5.2). Valve-related mortality at 20 years is 13% 
with a 3.3% incidence of thromboembolism per year. There 
was no incidence of structural deterioration. 
Magovern et al. (52) have reviewed the status of 130 
patients who underwent mitral valve replacement with or 
without concomitant coronary artery bypass grafting. Over- 
all mortality was 9.2%, whereas the subgroup with mitral 
regurgitation and coronary artery disease had the highest 
mortality rate (21.7%). Factors associated with death were 
preoperative functional class IV or cardiogenic shock, age 
>60 years or a left ventricular end-diastolic pressure of 15 
mm Hg. 
Mitral regurgitation. The majority of patients with mitral 
regurgitation can be successfully treated by mitral valve 
repair rather than replacement. Although Carpentier (53) 
remains the international authority on mitral valve repair, 
the techniques of mitral annular plication, annuloplasty ring 
insertion and repair of chordae tendineae rupture were well 
described by Kay et al. (45) in l%O. Repair of the mitral 
valve is preferred as it is associated with a lower actuarial 
probability of anticoagulation hemorrhage and higher actu- 
arial incidence of freedom from thromboembolism when 
compared with prosthetic replacement of the mitral valve 
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(54). In patients with ischemic mitral regurgitation, mitral 
valve repair results in improved operative survival when 
compared with mitral valve replacement (55). 
tricular performance and reduce operative mortality. 
A variety of new and innovative techniques for repairing 
regurgitant mitral valves have been described. Major ante- 
rior leaflet prolapse can be dealt with by chordal transposi- 
tion from the posterior leaflet (56) or creation of a neochorda 
with use of a strip of tissue from the anterior leaflet itself 
(57). In the event the mitral valve must be replaced, it is 
thought that preservation of the posterior leaflet and subval- 
vular apparatus (5859) and even the chordae tendineae to 
the anterior leaflet (60) will enhance postoperative left ven- 
this age group was most readily accomplished by resection 
of the coarctation and end to end anastomosis (71), but the 
rate of 3.5% and a negligible recurrence rate (75). 
mortality rate was high (43%) (70) and recoarctation was 
common (72). The introduction of the subclavian flap proce- 
dure by Waldhausen and Nahrwold (73) obviated this prob- 
lem to a large degree. The current standard of care in the 
treatment of neonates and infants with coarctation of the 
aorta is to initially stabilize the decompensated heart of the 
neonate by infusing prostaglandin E, to maintain ductal 
patency, which allows perfusion of the distal aorta from the 
patent ductus. Early subclavian flap repair using absorbable 
suture (74) can be accomplished with an operative mortality 
Aortic Valve Disease 
Aartic valve replacement. The origins of aortic valve 
surgery date back to 1954, when Hufnagel et al. (61) suc- 
cessfully introduced a ball-valve chamber into the cross- 
clamped descending thoracic aorta in patients with aortic 
insufficiency. Again, the introduction of cardiopulmonary 
bypass permitted subcoronary aortic valve replacement. A 
mechanical prosthesis was first inserted in the aortic position 
by Harken et al. (62) in 1960, whereas Ross (63) implanted 
the first aortic homograft in 1962. 
Magovem et al. (64) reviewed results in 259 patients who 
underwent aortic valve replacement with or without con- 
comitant coronary artery bypass grafting. Operative mortal- 
ity was highest in patients undergoing aortic valve replace- 
ment and coronary artery bypass grafting (13.5% versus 
3.5%). The strongest predictors of operative death were 
emergency operation and patient age over 70 years. Factors 
associated with late death were preoperative age, male 
gender, left ventricular end-diastolic pressure, cardiac index 
and functional class. 
Atrial septal defect. This is one of the most common 
congenital cardiac lesions, accounting for 10% to 15% of 
patients with congenital heart disease. This was the first 
defect successfully corrected with use of cardiopulmonary 
bypass, a feat accomplished by Gibbon (76) in 1953. The 
surgical management of uncomplicated atria1 septal defects 
has changed little during the past 35 years, with most centers 
reporting operative mortality rates for elective closure of 
<l% (77). 
Aortic stenosis: balloon vahloplasty. Aortic stenosis in 
elderly, high risk patients has most recently been managed 
by balloon valvuloplasty. It appears that this procedure may 
produce suboptimal results (65) and can potentially lead to 
annular disruption (66). It is unlikely that results with this 
method should be much different from those of the closed 
methods described in the 1950s by Bailey et al. (67) and long 
since abandoned as ineffective and dangerous. The high risk 
patient population may be smaller than anticipated in that at 
least two recent reports (68,69) document the safety of aortic 
valve replacement in the elderly. 
Ventricular septal defect. This is the most common of all 
congenital cardiac lesions, accounting for 25% of all congen- 
ital heart defects. Before the advent of cardiopulmonary 
bypass, patients with ventricular septal defect and high 
pulmonary flow were managed with a pulmonary artery band 
(78). Subsequent intracardiac repair was accomplished with 
minimal morbidity and mortality (79); however, pulmonary 
artery reconstruction is frequently required after removal of 
the band. Currently, primary repair of a ventricular septal 
defect can routinely be accomplished in symptomatic infants 
using cardiopulmonary bypass, deep hypothermia and total 
circulatory arrest (80). Pulmonary artery banding is now 
reserved for symptomatic infants with multiple muscular 
septal defects in whom the risk of early primary intracardiac 
repair remains significant (81). 
Congenital Cardiac Disease 
Atrioventricular (AV) canal. Before 1969, infants with an 
AV canal defect were primarily managed with a pulmonary 
artery band (82). Palliation was preferred as the results of 
corrective operation were less than encouraging. The first 
large series of patients who had undergone complete surgical 
repair of an endocardial cushion defect was reported by Ellis 
et al. (83) in 1960. The average age of these 66 patients was 
8 to 12 years and the hospital mortality rate was 21% (67% 
among patients undergoing repair of complete AV canal). A 
better understanding of the anatomic details of endocardial 
cushion defects, based on Rastelli’s classification (84), led to 
improved operative results (85) and the application of cor- 
rective surgery to infants with a complete AV canal (86). 
Currently, corrective surgery is recommended in older pa- 
tients with a complete AV canal who have not developed 
pulmonary vascular obstructive disease, whereas the use of 
cardiopulmonary bypass and hypothermic circulatory arrest 
Coarcttion of aorta. Twenty-five years ago it was gen- 
erally agreed that aortic coarctation should be repaired when 
diagnosed in children and adults. At that time, however, 
there was considerable disagreement regarding optimal man- 
agement of infants with coarctation (70). Surgical repair in 
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permits early repair in symptomatic infants with acceptable 
results (87). 
Tetralog?i of Fallot. This was the first complex congenital 
heart defect to be palliated with a systemic to pulmonary 
artery shunt. The Blalock-Taussig shunt was first performed 
on a 16 month old girl with tetralogy of Fallot in November 
1944 (88). This complex congenital cardiac anomaly was also 
the first to be totally corrected, in an operation performed by 
Scott et al. (89) in 1954, using hypothermia and circulatory 
arrest. L,illehei et al. (90) performed a successful intracardiac 
repair using cross-circulation in 1955, whereas Kirklin et al. 
(91) performed lhe first complete repair using cardiopulmo- 
nary bypass. Gustafson et al. (92) recently reported on the 
early intracardiac repair of tetralogy of Fallot in 40 infants. A 
right ventricular outflow tract patch was utilized in 34 
patients (85%), of whom the youngest was 7 weeks old. 
Follow-up extended from 2 to 37 months, at which time no 
residual ventricular septal defect and only one moderate 
right ventricular outflow tract gradient was observed. The 
authors state that the only infants undergoing a shunt pro- 
cedure initially were those with pulmonary atresia. complete 
AV canal or coronary anomalies. Kirklin et al. (93), how- 
ever, believe that a two stage approach is still indicated in 
infants under 6 months of age. 
Transposition of great arteries. In 1959 Senning (94) de- 
scribed a technique for the atrial repair of transposition of 
the great arteries. By 1970, Waldhausen et al. (95) reported 
a series of I2 patients with simple transposition in whom a 
second type of atrial baffle, the Mustard procedure (96). was 
performed with no mortality. Senning’s original report (94) 
also described the steps that would be required for surgical 
correction of the arterial side of transposition of the great 
arteries. ‘The latter procedure involved suturing the ventric- 
ular septum to the right of the aortic valve, and the proximal 
pulmonary artery, with its valve, to the right ventricular free 
wall. Although Senning’s arterial repair never achieved the 
popularity of his atrial baffle. a single stage arterial repair is 
now possible using the arterial switch operation described by 
Jatene et al. (97). 
Currently, simple transposition of the great arteries can 
he managed by either an atria1 ha@e or an urterial switch 
operation. A 20 center cooperative study (98) that random- 
ized infants to each of three surgical management strategies 
(Mustard, Senning or arterial switch operation) showed the 
survival and incidence of the need for reoperation to be 
similar among all groups. On the basis of a series of 23 
infants with transposition of the great arteries and an intact 
ventricular septum who underwent an arterial switch proce- 
dure in the 1st month of life. ldriss et al. (99) proposed that 
the atrial baffle be reserved for patients with anatomic or 
functional left ventricular inadequacy. Idriss (100) and Nor- 
wood (101) and their co-workers also demonstrated the 
efficacy of the arterial switch operation in patients with 
transposition of the great arteries and a ventricular septal 
defect. It appears that early anatomic repair results in good 
preservation of right and left ventricular function, avoiding 
the riced for additional palliative procedures (102). In addi- 
tion. the socioeconomic advantages of performing a defini- 
tive repair in the 1st weeks of life demand consideration. 
Complex anomalies. The modified Fontan procedure has 
now been applied to lesions other than classic tricuspid 
atresia. Infants with a single ventricle heart or double outlet 
right ventricle and noncommitted ventricular septal defect 
can undergo an early modified Fontan procedure with right 
atrial to pulmonary artery anastomosis with minimal mortal- 
ity (103). Total cavopulmonary connection has similar clin- 
ical applicability for the Fontan procedure and is associated 
with a reduced risk of postoperative arrhythmias and atrial 
thrombosis (104). 
Hypoplastic left heart syndrome. Before the development 
of the Norwood procedure (105) in 1981. infants with the 
hypoplastic left heart syndrome uniformly died within the 1st 
week of life. Recently, Norwood et al. (106) reviewed the 
status of 104 infants who underwent palliative reconstruction 
for hypoplastic left heart syndrome. They noted no contrain- 
dication to palliation. Lessons learned in this large series 
include the need for wide excision of the septum primum to 
avoid late pulmonary venous obstruction, patch closure of 
the main pulmonary artery to avoid loss of continuity 
between the right and left pulmonary arteries and the advan- 
tage of a central shunt that avoids relative hypoplasia of the 
left pulmonary artery associated with a modified right Bla- 
lock-Taussig shunt. 
Congenital aortic stenosis. This is one of the more com- 
mon cardiac anomalies, but results of operative intervention 
in the neonate with critical aortic stenosis remain poor. 
Brown et al. (107) described 257 patients with aortic stenosis 
and noted that the operative mortality rate in infants older 
than 6 months of age was 4%, whereas neonates with critical 
aortic stenosis had a 60% mortality rate. More recently, 
Turley et al. (108) reported on 33 patients who underwent 
either open valvotomy (25 patients) or transventricular dila- 
tion (8 patients). The hospital survival rate was 85% with no 
significant difference between methods. Our most recent 
experience also show, that a simple transventricular dilation 
of the stenotic valve in neonates gives excellent results with 
a very low mortality. 
Patients with supravalvular or suhvalvular uortic stenosis 
and those undergoing aortic valse replacement had a reduc- 
tion or elimination of associated aortic insufficiency. Con- 
versely, patients requiring valvotomy for valvular aortic 
stenosis developed a significant increase in the degree of 
aortic insufficiency (107). Infants with multilevel lesions 
required a complex repair with an attendant increase in 
mortality. Hammon et al. (109) studied a series of infants <6 
months of age who presented with critical valvular aortic 
stenosis and concluded that a small left ventricular dimen- 
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sion and elevated pulmonary artery pressure were predictive 
of a poor outcome. 
Aortic valve replacement. Children who require aortic 
valve replacement often have a small aortic anulus. Fleming 
and Sarafian (I IO) performed an aortic valve replacement 
and Konno ventriculoplasty in I6 patients aged 2 to 23 years. 
Eighty-one percent of patients received a valve ~25 mm. 
There was one operative death: postoperatively, all patients 
remain in New York Heart Association class I. Cardiac 
valve replacement in children is technically feasible, but the 
management of postoperative anticoagulation remains prob- 
lematic. Bioprostheses are to be avoided because of early 
leaflet calcification and valve failure. Sade et al. (I I I) 
previously reported the use of the St. Jude valve in children 
without anticoagulation, but recently withdrew this recom- 
mendation when a number of patients in their cohort devel- 
oped thromboembolic complications. Robbins et al. (I 12) 
observed a similar high incidence of thromboembolic com- 
plications in patients with a mechanical valve and no anti- 
coagulation. They concluded from their study of 94 children 
with a prosthetic cardiac valve that anticoagulation with 
warfarin could be safely employed. 
Cardiac Transplantation 
Human cardiac transplantation began in 1964 when 
Hardy et al. (I 13) transplanted a chimpanzee heart into a 68 
year old man. The patient survived for I h after the termi- 
nation of cardiopulmonary bypass. Cardiac allotransplanta- 
tion was first performed by Barnard (I 14) in 1967. The 
patient survived for I8 days but ultimately died of pneumo- 
nia. A number of centers developed cardiac transplan( 
programs (I l5), and early results indicated that the principal 
determinant of long-term survival was the successful man- 
agement of acute rejection. In the early 1970s immunosup- 
pression was based on the administration of prednisone, 
azathioprine and anti-human thymocyte globulin. Results 
with this triple drug regimen were less than satisfactory. as 
the I year survival rate in 1971 was 50% (I 151. 
Immunosuppressive therapy. Interest in cardiac trans- 
plantation waned in the subsequent decade but was renewed 
with the introduction of cyclosporin A (I 16). The effect of 
using cyclosporin A in combination with azathioprine and 
steroids is reflected in data reported by the International 
Society for Heart Transplantation (I l7), which indicate that 
5 year survival after cardiac transplantation now approaches 
80%. 
Political versus medical aspects of cardiac transplantation. 
The most revealing aspect of a recent literature review is the 
disturbingly large number of studies that deal with the 
“political” as opposed to “medical” aspects of cardiac 
transplantation. Limited donor organ availability has re- 
sulted in the adoption of a “routine inquiry” law in the 
majority of states (I IS). This law requires that hospital 
administrators or their designees advise families of deceased 
patients that their organs can be made available for trans- 
plantation. Even so, the rapid increase in the number of 
cardiac transplant centers has reduced the relative number 
of donor organs available to any institution. An attempt to 
expand the donor pool by harvesting organs from anenceph- 
alit infants has generated considerable controversy (I 19). 
Xenogeneic transplants. although technically feasible, re- 
main experimental (I 20). The most ominous development is 
the decision by the state of Oregon to limit funding available 
for organ transplantation (121). 
Recent experience. Bolman et al. (122) reviewed the 
transplantation experience at The Washington University 
during the past 2 years (59 patients. 62 heart transplants) and 
observed a number of well recognized trends. Low priority 
status patients usually experience a prolonged preoperative 
waiting period. Critically ill patients, requiring cardiotonic. 
ventilatory or mechanical circulatory support undergo trans- 
plantation more expeditiously, with reasonable results. With 
use of the combined immunosuppressive regimen of cyclos- 
porin. azathioprine and prednisone, 50% of patients were 
rejection free and 56% were infection free at I2 months. 
Role of patient age. Cardiac transplantation is now being 
otl’ered to both infants (123) and patients >60 years of age 
(124). Problems encountered in the pediatric population 
include the need for on-site donor harvesting because of 
intolerance of the neonatal heart to prolonged ischemia, as 
well as an inability to definitively diagnose rejection (123). In 
the series of Frazier et al. (124) of 28 patients >60 yedrS of 
age who underwent cardiac transplantation. the I year 
actuarial survival rate was 83%. Renlund et al. (125) propose 
that there may actually be an age-associated decline in 
cardiac allograft rejection due to a decrease in T effector 
cell-mediated immunity. 
Myocardial Preservation 
Crystalloid versus blood cardioplegia. The ideal constitu- 
ents and route of administration of cardioplegic solutions 
have yet to be determined. A rekindled interest in retrograde 
perfusion of the coronary sinus shows this technique to be 
efficacious in aortic valve replacement, elective myocardial 
revascularization ( 126) and repeat coronary artery bypass 
procedures (127). Standard anterograde perfusion of the 
aortic root with crystalloid and blood cardioplegic solutions 
has failed to demonstrate a distinct advantage to the use of 
either perfusate. One experimental study employing crystal- 
loid cardioplegia suggests that the volume of cardioplegic 
solution infused and the duration of infusion are the most 
significant determinants of the degree of myocardial protec- 
tion (128). Oxygenation of crystalloid cardioplegic perfusate 
(129.130) and hypothermia to ~20°C in either blood or 
crystalloid cardioplegia (131) also appear to result in a 
greater degree of myocardial preservation. Warner et al. 
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(132), in an experimental study, found that intermittent 
administration of blood cardioplegia resulted in a lower 
myocardial pH and hydrogen ion concentration when com- 
pared with crystalloid cardioplegia (132). Khuri et al. (133) 
described a clinical series in which blood cardioplegia was 
administered continuously while the aorta was cross- 
clamped. When compared with crystalloid or intermittent 
blood cardioplegia. continuous blood cardioplegia led to a 
marked reduction in myocardial acidosis and hydrogen ion 
concentration. 
Mechanical Circulatory Assistance 
Ventricular assist devices. The indications for use, tech- 
nique of implantation and principles of postoperative care in 
patients on a mechanical blood pump are well described. 
Ventricular assist devices are employed in patients with 
postcardiotomy cardiogenic shock and as a bridge to cardiac 
transplantation. Among patients with postcardiotomy ven- 
tricular failure, 41% to 50% can be weaned from their device, 
and 29% to 40% are discharged from the hospital (134, 
135.136). At an average follow-up interval of 29 months. 16 
of 23 survivors of mechanical ventricular assistance were 
either attending school or gainfully employed, whereas only 
4 patients had evidence of cardiac disability (New York 
Heart Association functional class III or IV) (137). Pae et al. 
(138) followed up nine ventricular assist pump survivors for 
an average of 31 months. All nine patients were in functional 
class IV preoperatively, whereas eight of nine were in 
functional class 1 or II after surgery. At least 50% of patients 
with end-stage cardiomyopathy who are supported with B 
ventricular assist device are able to undergo subsequent 
cardiac transplantation (139). 
Artificial heart. The pneumatically powered total artifi- 
cial heart is used primarily as a bridge to cardiac transplan- 
tation. A total of 41% to 88% of patients receive a cardiac 
allograft, whereas hospital discharge rates vary from 25% to 
50% (140,141). Sepsis precludes transplantation in many 
patients receiving mechanical circulatory support and limits 
long-term survival in patients who undergo cardiac trans- 
plantation (140,142). 
We gratefully acknowledge the assistance of Cynthia A. Miller m the 
preparation of the manuscript. 
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